Pharmaceutical The US Food and Drug Administration (FDA) has granted tentative approval of Liquidia Corp’s Yutrepia (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). 21 August 2024